Literature DB >> 28689332

Sex-specific incidence of EGFR mutation and its association with age and obesity in lung adenocarcinomas: a retrospective analysis.

Hye-Ryoun Kim1, Seo Yun Kim1, Cheol Hyeon Kim1, Sung Hyun Yang1, Jae Cheol Lee2, Chang-Min Choi2, Im Il Na3.   

Abstract

PURPOSE: Age and obesity are well-known risk factors for various cancers, but the potential roles of age and obesity in lung cancer, especially in those with activating EGFR mutations, have not been thoroughly evaluated. The aim of this retrospective study is to evaluate the associations between the sex-specific incidence of EGFR mutations and age and obesity.
METHODS: We conducted a retrospective study based on the data from 1378 lung adenocarcinoma cases. The degree of obesity was categorized by body mass index (BMI). The associations between EGFR mutational status and clinical factors, including stage, smoking history, age group (≤45 years, 46-55, 56-65 and >65), and BMI group (<18.5 kg/m2, 18.5-22.9, 23.0-24.9 and ≥25.0) were analyzed using logistic regression models for each sex.
RESULTS: In men, the incidence of EGFR mutation was inversely associated with age (adjusted odds ratio [OR] for age group = 0.76, p-trend = 0.003) and positively associated with obesity (adjusted OR for BMI group = 1.23, p-trend = 0.04). In contrast, in women, the incidence of EGFR mutation was positively associated with age (adjusted OR for age group = 1.19, p-trend = 0.02). However, the incidence of EGFR mutation was not statistically associated with obesity (adjusted OR for BMI group = 1.03, p-trend = 0.76).
CONCLUSIONS: Our data suggests that age and obesity may contribute to the sex-specific incidence of EGFR mutation in lung adenocarcinoma in different manners.

Entities:  

Keywords:  Age; EGFR mutation; Obesity; Sex

Mesh:

Substances:

Year:  2017        PMID: 28689332     DOI: 10.1007/s00432-017-2473-8

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  50 in total

Review 1.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

2.  Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.

Authors:  Yang Zhang; Yihua Sun; Yunjian Pan; Chenguang Li; Lei Shen; Yuan Li; Xiaoyang Luo; Ting Ye; Rui Wang; Haichuan Hu; Hang Li; Lei Wang; William Pao; Haiquan Chen
Journal:  Clin Cancer Res       Date:  2012-02-08       Impact factor: 12.531

Review 3.  Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors.

Authors:  L N Klapper; M H Kirschbaum; M Sela; Y Yarden
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

Review 4.  Biology of aging and cancer.

Authors:  Vladimir N Anisimov
Journal:  Cancer Control       Date:  2007-01       Impact factor: 3.302

Review 5.  The underlying basis for obesity: relationship to cancer.

Authors:  George A Bray
Journal:  J Nutr       Date:  2002-11       Impact factor: 4.798

Review 6.  The EGF receptor family as targets for cancer therapy.

Authors:  J Mendelsohn; J Baselga
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

7.  Cytochrome P450 1B1-mediated estrogen metabolism results in estrogen-deoxyribonucleoside adduct formation.

Authors:  Alexandra R Belous; David L Hachey; Sheila Dawling; Nady Roodi; Fritz F Parl
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

8.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

9.  Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung.

Authors:  Luke T Nordquist; George R Simon; Alan Cantor; W Michael Alberts; Gerold Bepler
Journal:  Chest       Date:  2004-08       Impact factor: 9.410

10.  Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR.

Authors:  Sang Yun Ha; So-Jung Choi; Jong Ho Cho; Hye Joo Choi; Jinseon Lee; Kyungsoo Jung; Darry Irwin; Xiao Liu; Maruja E Lira; Mao Mao; Hong Kwan Kim; Yong Soo Choi; Young Mog Shim; Woong Yang Park; Yoon-La Choi; Jhingook Kim
Journal:  Oncotarget       Date:  2015-03-10
View more
  6 in total

1.  Gender effects on quality of life and symptom burden in patients with lung cancer: results from a prospective, cross-cultural, multi-center study.

Authors:  Myriam Koch; Marianne Jensen Hjermstad; Krzysztof Tomaszewski; Iwona Tomaszewska; Kjersti Hornslien; Amelie Harle; Juan Arraras; Ofir Morag; Cecilia Pompili; Georgios Ioannidis; Chiara Navarra; Weichu Chie; Colin Johnson; Thomas Bohrer; Annelies Janssens; Dagmara Kulis; Andrew Bottomley; Christian Schulz; Florian Zeman; Michael Koller
Journal:  J Thorac Dis       Date:  2020-08       Impact factor: 2.895

2.  Obesity and nonalcoholic fatty liver disease associated with adenocarcinoma in patients with lung cancer.

Authors:  Chan-Yan Zhu; Ji-Chen Qu; Hai-Xia Cao; Guang-Yu Chen; Yi-Hai Shi; Jian-Gao Fan
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

3.  The Relationship between Long Noncoding RNA H19 Polymorphism and the Epidermal Growth Factor Receptor Phenotypes on the Clinicopathological Characteristics of Lung Adenocarcinoma.

Authors:  Yao-Chen Wang; Shih-Ming Tsao; Yia-Ting Li; Chia-Yi Lee; Thomas Chang-Yao Tsao; Ming-Ju Hsieh; Shun-Fa Yang
Journal:  Int J Environ Res Public Health       Date:  2021-03-11       Impact factor: 3.390

4.  Psychosocial Burden and Quality of Life of Lung Cancer Patients: Results of the EORTC QLQ-C30/QLQ-LC29 Questionnaire and Hornheide Screening Instrument.

Authors:  Myriam Koch; Laura Gräfenstein; Julia Karnosky; Christian Schulz; Michael Koller
Journal:  Cancer Manag Res       Date:  2021-08-07       Impact factor: 3.989

5.  Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma.

Authors:  Chan Shen; Rolfy A Perez Holguin; Eric Schaefer; Shouhao Zhou; Chandra P Belani; Patrick C Ma; Michael F Reed
Journal:  BMC Health Serv Res       Date:  2022-04-09       Impact factor: 2.655

6.  Gender Differences in Quality of Life of Metastatic Lung Cancer Patients.

Authors:  Myriam Koch; Frederike Rasch; Tobias Rothammer; Karolina Müller; Arno Mohr; Michael Koller; Christian Schulz
Journal:  Cancer Manag Res       Date:  2022-10-11       Impact factor: 3.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.